Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Douglas F. Kling, Chief Operating Officer of NewAmsterdam Pharma, reported significant insider transactions on June 16, 2025:
- Exercised stock options to acquire 100,000 total ordinary shares: - 78,101 shares at $10.00 per share - 21,899 shares at $10.90 per share
- Subsequently sold 100,000 shares in two tranches: - 81,891 shares at weighted average price of $19.19 - 18,109 shares at weighted average price of $19.75
- Post-transactions, Kling retains: - 44,000 ordinary shares - 372,829 options at $10.00 strike price - 261,314 options at $10.90 strike price
The transactions were executed under a Rule 10b5-1 trading plan. The sales represent a partial liquidation of Kling's holdings while maintaining significant equity exposure through remaining shares and options.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
FAQ
How many NewAmsterdam Pharma Co N.V. (NAMSW) SEC filings are available on StockTitan?
StockTitan tracks 73 SEC filings for NewAmsterdam Pharma Co N.V. (NAMSW), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.
When was the most recent SEC filing for NewAmsterdam Pharma Co N.V. (NAMSW)?
The most recent SEC filing for NewAmsterdam Pharma Co N.V. (NAMSW) was filed on June 26, 2025.